Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy

References

• Young R H. The pathology of bladder cancer. Textbook of genitourinary oncology, N J Vogelzang, P T Scardino, W U Shipley, D S Coffey. Williams and Wilkins, Philadelphia, PA 1996; 326–37
   Google Scholar
• Gospodarowicz M K, Quilty P M, Scalliet P, Tsujii H, Fossa S D, Horenblas S, et al. The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 1995; 2(Suppl 2)41–8
   Google Scholar
• Zietman A L, Shipley W U, Kaufman D S. The combination of cis-platinum based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Radiat Oncol Biol Phys 1993; 27: 161–70
   PubMedGoogle Scholar
• Javie M, Raghavan D. Systemic therapy for invasive bladder cancer. Cancer Control 1996; 3: 501–6
   Google Scholar
• McDougal W S. Continent urinary diversion. Urologic oncology, J E Osterling, J P Richie. WB Saunders, Philadelphia, PA 1997; 336–40
   Google Scholar
• Jung P, Jaske G. Bladder preservation in invasive locally confined bladder cancer (in German). Onkologie 1996; 19: 296–301
   Google Scholar
• Geven K M, Spera J A, Solin L J, Morgan T, Hanks G E. Local control after cystectomy alone in bladder carcinoma. Cancer 1992; 69: 2767–70
   Google Scholar
• Martinez-Pineiro J A, Martin M G, Arocena N F, Flores N, Roncero C R, Portillo J A, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153: 964–73
   PubMed Web of Science ®Google Scholar
• Pressler L B, Petrylak D P, Olsson C A. Invasive transitional cell carcinoma of the bladder: prognosis and management. Urologic oncology, J E Osterling, J P Richie. WB Saunders, Philadelphia, PA 1997; 275–91
   Google Scholar
• Hart S, Skinner E C, Meyerowitz B E, Boyd S, Lieskovsky G, Skinner D G. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, or cutaneous or urethral Kock pouch. J Urol 1999; 162: 77–81
   PubMed Web of Science ®Google Scholar
• Wallace D MA, Raghavan D, Kelly K, Sandemann T F, Conn I G, Teriana N, et al. Neoadjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608–12
   PubMedGoogle Scholar
• Hall R R. Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer: first analysis of MRC/EORTC intercontinental trial (abstract). Proc Am Soc Clin Oncol 1996; 15: 244
   Google Scholar
• Ghersi D, Stewart L A, Parmar M KB, Coppin C, Martinez-Pineiro J, Raghavan D, et al. Does neoadiuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 1995; 76: 206–13
   Google Scholar
• Malmstrom P U, Rintala E, Wahlquist R, Hellström P, Hellsten S, Hannisdal E. Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. J Urol 1996; 155: 1903–6
   PubMed Web of Science ®Google Scholar
• Skinner D G, Daniels J R, Russell C A. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459–64
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenberg W, Weller S, Vodes G, Gertenbach U, Thuroff J W, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2: improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 302–8
   PubMed Web of Science ®Google Scholar
• Freiha F, Reese J, Torti F. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495–500
   PubMed Web of Science ®Google Scholar
• Miller L S. Bladder cancer: superiority of preoperative radiation in cystectomy in clinical stage T3. Cancer 1977; 39: 973–80
   PubMed Web of Science ®Google Scholar
• Horwich A, Pendlebury S, Dearnaley D P. Organ conservation in bladder cancer. Eur J Cancer 1995; 31(Suppl 5)208
   Google Scholar
• Sell A, Jakobsen A, Nerstrom B, Sorensen B L, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2, T3, T4a. A randomized multicenter study of preoperative indication and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scan J Urol Nephrol Suppl 1991; 138: 193–201
   PubMedGoogle Scholar
• Shipley W U, Zietman A L, Kaufman D S, Althausen A F, Heney N M. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys 1997; 39: 937–43
   Google Scholar
• Schultz T K, Herr H W, Zhang Z F. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival in patients treated with MVAC with 5-year follow-up. J Clin Oncol 1994; 12: 1394–401
   PubMedGoogle Scholar
• Herr H W. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987; 138: 1162–3
   PubMed Web of Science ®Google Scholar
• Henry K, Miller J, Mort M, Loening S, Fallon B. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 1988; 140: 964–7
   PubMed Web of Science ®Google Scholar
• De Neve W, Lybeert M L, Goor C, Grommelin M A, Ribot J G. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995; 36: 183–8
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M K, Hawkins M C, Rawling G A, Connoly J G, Jewett M AS, Thomas G M, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989; 142: 1448–54
   PubMed Web of Science ®Google Scholar
• Jenkins B J, Caulfield M J, Fowler C G, Badenoch D F, Tiptaft R C, Paris A M, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder cancer. Br J Urol 1988; 62: 343–6
   PubMedGoogle Scholar
• Mameghan H, Fisher R, Mameghan J. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995; 31: 247–54
   PubMed Web of Science ®Google Scholar
• Shearer R J, Chilvers C E, Bloom H JG, Bliss J M, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. Br J Urol 1988; 62: 558–64
   PubMedGoogle Scholar
• Hall R R. Transurethral resection for transitional cell carcinoma. Problems Urol 1992; 6: 460–70
   Google Scholar
• Quilty P, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 1986; 12: 853–60
   PubMed Web of Science ®Google Scholar
• Smaaland R, Akslen L A, Tonder B. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol 1991; 67: 61–9
   PubMedGoogle Scholar
• Farah R, Chodak G W, Vogelzang N I. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys 1991; 20: 413–7
   Google Scholar
• Hall R R, Roberts J T. Neoadjuvant chemotherapy, a method to conserve the bladder. Proceedings of the 6th European Conference on Oncology and Cancer Nursing, FlorenceItaly, Oct, 22–291991, Eur J Cancer 1991, 27 Suppl 2: abstract 144
   Google Scholar
• Keating J, Zincke H, Morgan W R. Extended experience with neoadjuvant M-VAC chemotherapy for invasive transitional cell carcinoma of the urinary bladder. J Urol 1989; 141: 244a
   Google Scholar
• Kurth K II, Splinter T A, Jacqmin D. Transitional cell carcinoma of the bladder: a phase II study of chemotherapy in T3–4 NO MO of the EORTC GU group. Urological oncology dilemmas and developments, A R Alderson, R T Oliver, I W Hanham, H J Bloom. Wiley-Liss, New York, NY 1991; 115–28
   Google Scholar
• Maffezzini M, Torelli T, Villa E, Corrada P, Bolognesi A, Leidi G L, et al. Systemic preoperative chemotherapy with cisplatin, methotrexate, and vinblastine for locally advanced bladder cancer: local tumor response and early follow-up results. J Urol 1991; 145: 741–3
   Google Scholar
• Roberts J T, Fossa S P, Richards S B, Kaye S B, White E F, Robinson M C, et al. Results of Medical Research Council Phase 11 Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. BY J Urol 1991; 68: 162–8
   PubMedGoogle Scholar
• Hall R R, Newling D WW, Ramsden P D, Richards B, Robinson M R, Smith P H. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984; 56: 668–72
   Google Scholar
• Parsons J T, Million R R. Bladder cancer. Principles and practice of radiation oncology, C A Perez, I W Brady. Lippincot, Philadelphia, PA 1991; 1036–58
   Google Scholar
• Prout G R, Shipley W U, Kaufman D, Heney N M, Griffin P P, Althausen A F, et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol 1990; 144: 1128–34
   Google Scholar
• Scher H I, Herr H W, Sternberg C, Fair W, Bod G, Sogani P, et al. Neoadjuvant chemotherapy for invasive bladder cancer. Experience with the MVAC regimen. Br J Urol 1989; 64: 250–6
   PubMedGoogle Scholar
• Cervak J, Cufer T, Marolt F. Combined chemotherapy and radiotherapy in muscle-invasive bladder carcinoma. Complete remission results. Proceedings of the 6th European Conference on Oncology and Cancer Nursing, FlorenceItaly, Oct, 22–291991, Eur J Cancer 1991, 27 Suppl 2: abstract 561
   Google Scholar
• Dunst J, Sauer R, Schrott K M, Kuhn R, Wittekind C, Altendorf-Hofmann A, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994; 30: 261–6
   PubMed Web of Science ®Google Scholar
• Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85–12. Int J Radiat Oncol Biol Phys 1993; 25: 783–90
   PubMed Web of Science ®Google Scholar
• Tester W, Porter A, Heaney J, Whittington R, Byhardt R, True L, et al. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer. J Clin Oncol 1996; 14: 119–26
   PubMedGoogle Scholar
• Kachnic L A, Kaufman D S, Griffin P P, Heney N M, Althausen A F, Zietman A L, et al. Bladder preservation by combined modality therapy in invasive bladder cancer. J Clin Oncol 1997; 15: 1022–7
   PubMed Web of Science ®Google Scholar
• Shipley W U, Winter K A, Lee R, Kaufman D S, Heney N M, Tester W J, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89–03. J Clin Oncol 1998; 16: 3576–83
   PubMed Web of Science ®Google Scholar
• Housset M, Dufour E, Maulard-Durtux C. Concomitant 5-fluouracil - cisplatin and bifractionated split course radiation therapy for invasive bladder cancer (abstract). Proc Am Soc Clin Oncol 1997; 16: 319
   Google Scholar
• Housset M, Maulard C, Chretien Y C, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2150–7
   PubMed Web of Science ®Google Scholar
• Given R W, Parsons J T, McCarley D. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a 5-year follow up. Urology 1995; 46: 499–505
   PubMedGoogle Scholar
• Sauer R, Berkenhage S, Kuhn R. Efficacy of radiochemo-therapy with Platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 121–7
   PubMed Web of Science ®Google Scholar
• Shipley W U, Kaufman D S, Heney N M, Althausen A F, Zietman A L. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999; 162: 445–51
   PubMedGoogle Scholar
• Cole D, Durrant K, Roberts J, Dawes P J, Yosef H, Hopewell J W. A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 1992; 65: 792–8
   PubMedGoogle Scholar
• Zietman A L, Kaufman D S, Shipley W U, Park J J, Althausen A F, Gomery P, et al. A Phase MI trial of transurethral surgery plus Cisplatin and radiation therapy followed either by selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis. J Urol 1998; 160: 1673–7
   PubMed Web of Science ®Google Scholar
• Lynch W, Jenkins B, Fowler C. The quality of life after radical radiotherapy for bladder cancer. Br J Urol 1992; 70: 519–21
   PubMedGoogle Scholar
• Kachnic L A, Shipley W U, Griffin P P, Zietman A L, Kaufman D S, Althausen A F, et al. Combined modality treatment with bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. Cancer J Sci Am 1996; 2: 79–83
   PubMedGoogle Scholar
• Little F A, Howard G C. Sexual function following radical radiotherapy for bladder cancer (abstract). Radiother Oncol 1998; 48: 87
   Google Scholar